Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Februar 2026 10:00 ET | Quelle: Siren Biotechnology, Inc.

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
23. Februar 2026 08:00 ET | Quelle: Alps Group Inc

Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...
20. Februar 2026 08:00 ET | Quelle: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
19. Februar 2026 21:40 ET | Quelle: Candel Therapeutics

Candel Therapeutics Announces Pricing of Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
19. Februar 2026 10:48 ET | Quelle: Research and Markets

Claudin 18.2-Targeted Immunotherapy Pipeline Market Research Report 2026: an Up-to-date Competitor Evaluation in the Field of Therapy Candidates in Research and Development

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Claudin 18.2-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
19. Februar 2026 10:46 ET | Quelle: Research and Markets

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Research Report 2026: More Than 20 Distinct Molecules Targeting the CD47-SIRP-a Pathway are in Clinical Development

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
17. Februar 2026 10:13 ET | Quelle: Research and Markets

Immunotherapy Drugs Market Research and Forecast Report, 2020-2025/2025-2026 with Analyst Recommendations - Adoption of AI in Drug Discovery / Combination Therapies

Dublin, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The "Immunotherapy Drugs Market (2026 Edition)" report has been added to ResearchAndMarkets.com's offering.The global immunotherapy drugs market is...
12. Februar 2026 08:00 ET | Quelle: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
05. Februar 2026 08:30 ET | Quelle: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
03. Februar 2026 21:30 ET | Quelle: MiNK Therapeutics

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration...

Nächste Seite